[ Pharmaceutical Sciences Asia - ONLINE ]
E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974

 
Abstracts

DOI: 10.29090/psa.2024.02.24.912Pharm Sci Asia 2024; 51(2), 125-132
 

Comparison of lactate clearance between high-dose and conventional-dose of meropenem in sepsis and septic shock patients at emergency department; post-hoc analysis of a randomized controlled trial

Pitsucha Sanguanwit1, Preecha Montakantikul2, Pakkaporn Damrongkulchart1, Tospon Lertwattanachai3, Viratch Tangsujaritvijit4, Pitchaya Dilokpattanamongkol*

1 Department of Emergency Medicine, Faculty of medicine Ramathibodi hospital Mahidol University, 270, Rama 6 Road, Phayathai, Ratchathewi, Bangkok, Thailand
2 Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri Ayuthaya Road, Rajathewi, Bangkok, Thailand
3 Department of Pharmacy, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, 681 Thanon Samsen, Wachira Phayaban, Dusit District, Bangkok, Thailand
4 Department of Pharmacy, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, 681 Thanon Samsen, Wachira Phayaban, Dusit District, Bangkok, Thailand


In sepsis and septic shock, patients often face hemodynamic instability, resulting in fluid leakage, heightened capillary permeability, increased distribution volume, and compromised antimicrobial concentrations. Lactate clearance is a well-established marker of illness severity, particularly in the context of sepsis, where it serves as a reliable predictor of mortality. It is notably useful in the determination of resuscitation endpoints. This study aimed to compare lactate clearance within 6 hours between two meropenem dose groups. We conducted a secondary analysis of a randomized controlled trial involving participants aged 18 or older, diagnosed with sepsis and septic shock as per sepsis-3 criteria, and receiving meropenem in an emergency department (ED) setting. The study occurred between December 1, 2017, and August 31, 2018. Of 43 patients, 21 (48.84%) were in the high-dose meropenem group and 22 (51.16%) in the conventional-dose group. Remarkably, a significantly higher proportion of patients in the high-dose group achieved lactate clearance greater than 10% within 6 hours compared to the conventional-dose group (95.2% vs. 63.6%, P=0.01). Lactate clearance greater than 10% at 3 days was 85.7% and 86.4% in the high-dose and conventional-dose groups, respectively (P=0.95). For 30-day mortality, there were 14.3% and 22.7% in the high-dose and conventional-dose groups, respectively (P=0.47). High-dose patients had 18.0 hospital-free days (range 0 to 24) versus 10.0 days (range 0 to 17.0) in the conventional-dose group (P=0.17). In summary, this study highlights a higher rate of sepsis and septic shock patients in the high-dose group achieving lactate clearance within 6 hours. This suggests potential benefits linked to the high-dose meropenem regimen for this specific group of patients.


Keyword:

Meropenem, Sepsis, Septic shock, Lactate clearance, Emergency Department




Download full paper (PDF File size: 546.83 KB.)





Vol.51
No.4
October-December 2024

See other volume

 


Vol.51
No.3
July-September 2024

See other volume

 


Vol.51
No.2
April-June 2024

See other volume

 


Vol.51
No.1
January-March 2024

See other volume

 
 
 

Home
Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
Announcement
All Volumes & Issues
Submit Online
Contact us
   
Search
   
Faculty of Pharmacy Mahidol University
Mahidol University
Member's menu

You're now loging on with following account:
Guest (unknown)

Please Sign in or Register



Pharmaceutical Sciences Asia by Faculty of Pharmacy, Mahidol University, Thailand is licensed under CC BY-NC-ND 4.0

    Copyright © 2017-2024
    Faculty of Pharmacy, Mahidol University, THAILAND
 

We use Cookies

This site uses cookies to personalise your experience and analyse site traffic. By Clicking ACCEPT or continuing to browse the site you are agreeing to our use of cookies.